Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

JNJ-56136379 · JNJ-6379

Small molecule · developed by Janssen Sciences Ireland UC

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is JNJ-56136379?

JNJ-56136379 is an investigational small-molecule drug studied in Hepatitis B.

At a glance

Also known as
JNJ-6379
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Janssen Sciences Ireland UC
In trials of
ARWR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
2456KW2166

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03365947 Phase 1/2 Hepatitis B Completed ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis B

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.